Eccrine squamous syringometaplasia secondary to pegylated liposomal doxorubicin.
Garcia-Navarro
Xavier
X
Puig
Lluis
L
Fernández-Figueras
Maria T
MT
Alomar
Agustíin
A
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects; D001707:Biopsy, Needle; D004317:Doxorubicin / Q000009:adverse effects / Q000031:analogs & derivatives*; D004439:Eccrine Glands / Q000187:drug effects / Q000473:pathology; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D004890:Erythema / Q000139:chemically induced*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D008679:Metaplasia / Q000139:chemically induced; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects*; D018570:Risk Assessment; D013544:Sweat Gland Neoplasms / Q000139:chemically induced* / Q000473:pathology; D018252:Syringoma / Q000139:chemically induced* / Q000473:pathology
D000903:Antibiotics, Antineoplastic; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin